https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53150 Wed 29 May 2024 15:41:34 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13691 Wed 11 Apr 2018 17:01:07 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14107 Wed 11 Apr 2018 12:31:05 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34574 Wed 04 Sep 2019 09:56:07 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48412 Thu 16 Mar 2023 14:03:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44444 2 = 8.197, P = 0.004), experienced (>4 years; X² = 34.635, P < 0.001), and having more training (>61 h; X² = 8.503, P = 0.004) were associated with reporting a major adverse event occurred during their career. Conclusions Half of physical therapists surveyed performed dry needling. Practice patterns were consistent with expert opinion. The number of adverse events reported suggests further research is needed to quantify the risks of dry needling. Participant characteristics associated with a major adverse event appear to be related to the number of exposures.]]> Thu 13 Oct 2022 12:18:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37046 Thu 13 Aug 2020 12:00:56 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1509 Sat 24 Mar 2018 08:30:53 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:11498 Sat 24 Mar 2018 08:10:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5497 70 years [odds ratio (OR) 1.9, 95% confidence intervals (CI) 1.3–2.6] and duration of operation (P = 0.005). Other predictive factors were: contaminated surgical site (OR 2.1, 95% CI 1.2–3.7) and anaemia (OR 1.8, 95% CI 1.1–2.8). Predictive factors of individual procedures included: urine retention (transurethral resection of the prostate); extended duration of operation and asthma (hysterectomy); acute admissions and extended duration of operation (cholecystectomy); and warfarin type drugs, ethanol abuse, failed prostheses, GI ulcer/ inflammation, rheumatoid arthritis, and ischaemic heart disease (hip and knee joint arthroplasty). Conclusions: The results of this study suggest that five factors should be routinely monitored for patients undergoing these procedures: age >70 years, type of procedure, duration of operation >2 h, contaminated surgical site and anaemia.]]> Sat 24 Mar 2018 07:47:01 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27255 Sat 24 Mar 2018 07:29:12 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4767 Sat 24 Mar 2018 07:20:41 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40051 40%. There is limited safety or efficacy data in patients with ppFEV1 < 40%. We determined whether LUM/IVA in patients with ppFEV1 < 40 would reduce the rate of pul- monary exacerbations. Methods: This was a case control study performed on patients > 12 years, homozygous for Phe508del CFTR mutation and with ppFEV1 < 40%. Control subjects were matched for age, sex and ppFEV1, and had mutations ineligible for LUM/IVA. We assessed the rate of pulmonary exacerbations requiring intravenous antibiotics, the mean rate of change in ppFEV1 over 12 months and all adverse events. Results: Data was collected from 7 Australian CF centres on 105 patients; 72 on LUM/IVA and 33 controls. LUM/IVA demonstrated a large reduction in exacerbations with an incident rate ratio of 0.455 (95%CI; 0.306 –0.676), p < 0.001 after adjusting for the number of exacerbations in the previous 12 months. LUM/IVA prolonged the time to first exacerbation and reduced the rate of decline in ppFEV1 over 12 months. Adverse events were common; chest tightness or dyspnoea was experienced by 55% and resulted in cessation of treatment in 32%. Conclusions: Treatment with LUM/IVA resulted in a substantially lower rate of pulmonary exacerbations, prolonged time to first exacerbation and slowed the rate of decline of ppFEV1 in participants with severe lung disease. Adverse reactions to LUM/IVA however were unacceptably frequent, and resulted in a very high discontinuation rate.]]> Fri 22 Jul 2022 13:27:19 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48457 3000 deaths prevented under high transmission. Risks versus benefits varied significantly between age groups and transmission levels. Under high transmission, deaths prevented by AZ vaccine far exceed deaths from TTS (by 8 to > 4500 times depending on age). Probability of dying from COVID-related atypical severe blood clots was 58–126 times higher (depending on age and sex) than dying from TTS. To our knowledge, this is the first example of the use of Bayesian networks for risk–benefit analysis for a COVID-19 vaccine. The model can be rapidly updated to incorporate new data, adapted for other countries, extended to other outcomes (e.g., severe disease), or used for other vaccines.]]> Fri 17 Mar 2023 12:07:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49361 Fri 12 May 2023 12:35:08 AEST ]]>